Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 2;3(3):e200423.
doi: 10.1001/jamanetworkopen.2020.0423.

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs

Alyson Haslam  1   2 , Jennifer Gill  1 , Vinay Prasad  1   3   4
Affiliations

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs

Alyson Haslam et al. JAMA Netw Open. .

Abstract

This cross-sectional study estimates the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Prasad reported receiving royalties from Johns Hopkins Press Health Books; funding from the Laura and John Arnold Foundation; honoraria for grand rounds and lectures from several universities, medical centers, and professional societies; and payments for contributions to Medscape. Dr Prasad hosts the podcast “Plenary Session,” which receives funding from Patreon backers. No other disclosures were reported.

Figures

Figure.
Figure.. Estimated Eligibility for Immune Checkpoint Inhibitor Drugs in Oncology, 2018 and 2019, Under Several Scenarios
The 2019 (A) bar includes limited updates from 2018 to 2019, removing the benefit of hepatocellular and gastric cancers but assuming a benefit to urothelial cancers from immunotherapy drugs (eg, avelumab) that have not had changes to US Food and Drug Administration (FDA) approval status. The 2019 (B) bar includes all updates from 2018 to 2019 and assumes that all immunotherapy drugs for urothelial cancer will have FDA limitations like atezolizumab and pembrolizumab have had. HNSCC indicates head and neck squamous cell carcinoma; MSI-H, microsatellite instability high; PDL1, programmed death–ligand 1. aCancer type affected by limitations in FDA approval. bCancer type excluded in 2019 estimates. cCancer type newly included in 2019 estimates.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. American Cancer Society Immune checkpoint inhibitors to treat cancer. https://www.cancer.org/treatment/treatments-and-side-effects/treatment-t.... Published 2018. Accessed January 10, 2010.
    1. Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019;2(5):e192535. doi:10.1001/jamanetworkopen.2019.2535 - DOI - PMC - PubMed
    1. Gill J, Prasad V. A reality check of the accelerated approval of immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2019;16(11):-. doi:10.1038/s41571-019-0260-y - DOI - PubMed
    1. US Food and Drug Administration FDA limits the use of Tecentriq and Keytruda for some urothelial cancer patients. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-limit.... Published July 5, 2018. Accessed August 9, 2019.
    1. University of Geneva Public domain antibiotic found highly effective against triple-negative breast cancer. https://medicalxpress.com/news/2019-03-domain-antibiotic-highly-effectiv.... Published March 29, 2019. Accessed August 9, 2019.

Substances